<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:53:37Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/30109" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/30109</identifier><datestamp>2026-09-24T05:00:12Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Bramson, Jonathan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Morris, Claire</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2024-08-28T15:20:24Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2024-08-28T15:20:24Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2024</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/30109</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/9219</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Creating a universal-prime boost strategy using multi-specific T cells from the&#xd;
tumour infiltrating lymphocytes (TIL) population can enhance the success of adoptive T&#xd;
cell therapies (ACT). ACT, as a personalized living-drug, is often a last resort due to its&#xd;
extensive time, cost, and labor requirements, making it largely inaccessible. Vaccines&#xd;
encoding personalized tumour-associated antigens (TAA) have proven to be potent&#xd;
boosters for ACT. This combination has shown success in (1) promoting T cell&#xd;
proliferation in vivo and (2) inducing immune infiltration into the solid tumour&#xd;
microenvironment. TIL offer a plethora of TAA-specific T-cell receptors (TCRs) when&#xd;
successfully isolated and expanded. Synthetic receptors can be engineered into TIL to&#xd;
recognize any specified antigen, including those matched in vaccines. Previously, we&#xd;
validated combining ACT with an oncolytic virus vaccine (OVV) “boost” through a&#xd;
synthetic receptor to promote in vivo expansion of naïve splenocytes in a proof-of-&#xd;
concept TCR-transgenic synergetic murine model. Here, we report on the feasibility of&#xd;
isolating and engineering polyclonal, tumour-specific T cells from TIL and tumour-&#xd;
draining lymph nodes, evaluating them functionally. We further investigate the matched&#xd;
CAR/OVV system in another distinct TCR transgenic model and return to the first proof-&#xd;
of-concept model to uncover the biological mechanisms of our combination therapy to&#xd;
improve anti-tumour efficacy. Uniting a universal OV vaccine with a matched universal&#xd;
CAR creates an “off-the-shelf” combination, allowing any T cell product to be&#xd;
engineered. This approach reduces the resource burden of traditional ACT, making it&#xd;
more accessible to all cancer types.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Health Sciences (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Adoptive T cell therapy (ACT) uses a patient's immune cells to fight cancer but is&#xd;
often a last resort due to high costs and labor. Our research aims to make ACT more&#xd;
accessible by combining it with therapeutic cancer vaccines that can contain any protein,&#xd;
including cancer proteins, and boost ACT’s effectiveness. We engineered T cells with&#xd;
synthetic receptors to recognize the vaccine’s protein and developed a universal system&#xd;
pairing these T cells with a specially designed oncolytic virus vaccine (OVV).&#xd;
This combination promotes T cell expansion and improves immune response against&#xd;
tumours. We tested this system in multiple models, demonstrating enhanced T cell&#xd;
function and tumour targeting in one model, but challenges in another. Investigating the&#xd;
mechanisms, we sought to identify ways to improve the therapy’s efficacy. Our "off-the-&#xd;
shelf" solution reduces costs and resources, making this powerful cancer treatment more&#xd;
accessible to a wider range of patients.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cancer</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Immunology</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Developing an engineered T cell product for universal vaccination-based boosting in adoptive cell therapies</dim:field>
   <dim:field mdschema="dc" element="title" qualifier="alternative" lang="en_US">Oncolytic virus vaccination to expand engineered T cells</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>